EP1150669A4 - L-arginine based formulations for treating diseases and methods of using same - Google Patents

L-arginine based formulations for treating diseases and methods of using same

Info

Publication number
EP1150669A4
EP1150669A4 EP00911701A EP00911701A EP1150669A4 EP 1150669 A4 EP1150669 A4 EP 1150669A4 EP 00911701 A EP00911701 A EP 00911701A EP 00911701 A EP00911701 A EP 00911701A EP 1150669 A4 EP1150669 A4 EP 1150669A4
Authority
EP
European Patent Office
Prior art keywords
methods
same
treating diseases
based formulations
arginine based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00911701A
Other languages
German (de)
French (fr)
Other versions
EP1150669A1 (en
Inventor
Wayne H Kaesemeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiogenix Inc
Original Assignee
Angiogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogenix Inc filed Critical Angiogenix Inc
Priority to EP06007096A priority Critical patent/EP1671630A3/en
Publication of EP1150669A1 publication Critical patent/EP1150669A1/en
Publication of EP1150669A4 publication Critical patent/EP1150669A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
EP00911701A 1999-02-05 2000-02-04 L-arginine based formulations for treating diseases and methods of using same Withdrawn EP1150669A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06007096A EP1671630A3 (en) 1999-02-05 2000-02-04 L-Arginine based formulations for treating diseases and methods of using the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11890399P 1999-02-05 1999-02-05
US118903P 1999-02-05
PCT/US2000/002798 WO2000045809A1 (en) 1999-02-05 2000-02-04 L-arginine based formulations for treating diseases and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06007096A Division EP1671630A3 (en) 1999-02-05 2000-02-04 L-Arginine based formulations for treating diseases and methods of using the same

Publications (2)

Publication Number Publication Date
EP1150669A1 EP1150669A1 (en) 2001-11-07
EP1150669A4 true EP1150669A4 (en) 2005-06-22

Family

ID=22381443

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00911701A Withdrawn EP1150669A4 (en) 1999-02-05 2000-02-04 L-arginine based formulations for treating diseases and methods of using same

Country Status (6)

Country Link
EP (1) EP1150669A4 (en)
JP (1) JP2002536325A (en)
AU (1) AU3356000A (en)
CA (1) CA2361575A1 (en)
MX (1) MXPA01007952A (en)
WO (1) WO2000045809A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968983A (en) 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
JP2002539257A (en) 1999-03-19 2002-11-19 イーノス・ファーマシューティカルス・インコーポレーテッド Increased drug bioavailability in the brain
JP5065570B2 (en) * 2002-09-06 2012-11-07 第一三共ヘルスケア株式会社 Vascular endothelial nitric oxide synthesis promoter
CN100400116C (en) * 2003-08-14 2008-07-09 兰色医药设备有限公司 Endoluminal prosthesis comprising a therapeutic agent
EP1591118A1 (en) * 2004-04-27 2005-11-02 Nutri-Fit GmbH & Co. KG Use of melatonin in preventing postoperative complications
JP2012041296A (en) * 2010-08-19 2012-03-01 Medience Corp Vascular endothelial function improving agent, nitric oxide production promoter, and food and drink

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0745332A1 (en) * 1995-06-01 1996-12-04 N.V. Nutricia Clinical nutritional composition
WO1999062509A1 (en) * 1998-06-01 1999-12-09 Nitromed, Inc. Endogenous nitric oxide synthesis under conditions of low oxygen tension

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
WO1994009786A1 (en) * 1992-11-04 1994-05-11 Sepracor, Inc. Methods and compositions of (+) doxazosin for the treatment of hypertension
CA2164632A1 (en) * 1993-06-11 1994-12-22 John P. Cooke Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
FR2774593B1 (en) * 1998-02-12 2000-05-05 Philippe Gorny OBTAINING A MEDICINE TO COMBAT FEMALE SEXUAL DYSFUNCTIONS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0745332A1 (en) * 1995-06-01 1996-12-04 N.V. Nutricia Clinical nutritional composition
WO1999062509A1 (en) * 1998-06-01 1999-12-09 Nitromed, Inc. Endogenous nitric oxide synthesis under conditions of low oxygen tension

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0045809A1 *

Also Published As

Publication number Publication date
JP2002536325A (en) 2002-10-29
AU3356000A (en) 2000-08-25
WO2000045809A1 (en) 2000-08-10
CA2361575A1 (en) 2000-08-10
EP1150669A1 (en) 2001-11-07
MXPA01007952A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
HK1037303A1 (en) Compositions and methods for treatment of mitochondrial diseases
HUP0301121A3 (en) Topical pharmaceutical formulations and methods of treatment
EP1227821A4 (en) Therapeutic compositions and methods of use thereof
HK1048247A1 (en) Stable carotene-xanthophyll beadlet compositions and methods of use
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU7880700A (en) Compositions and methods of treatment for skin conditions using extracts of turmeric
AU7748000A (en) Method and composition for the treatment of dermatologic diseases
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
AUPQ415899A0 (en) Compositions for and methods of treatment of allergic diseases
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
IL143594A0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
HUP0104963A3 (en) Compositions for the treatment of skin diseases
EP1150669A4 (en) L-arginine based formulations for treating diseases and methods of using same
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
IL141551A0 (en) Compositions and methods for the treatment of immune related diseases
EP1189584A4 (en) Alpha amino acid composition and method for the treatment of skin
AU2420101A (en) Method and composition for the treatment of pain
EP1173189A4 (en) Asialocytokines and treatment of liver disease
AU2566201A (en) Compounds and methods for the treatment of pain
GB9906808D0 (en) Formulation for treatment of pain
HUP0300043A3 (en) Method and composition for the treatment of pain
AU1621501A (en) Methods and compositions for treatment of disease
AU2002313992A1 (en) Compositions and Methods for Treatment of Mitochondrial Diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010829

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ANGIOGENIX, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 35/78 B

Ipc: 7A 61K 31/505 B

Ipc: 7A 61K 31/198 B

Ipc: 7A 61K 31/495 B

Ipc: 7A 61K 31/195 A

A4 Supplementary search report drawn up and despatched

Effective date: 20050503

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060411